Related references
Note: Only part of the references are listed.Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies
Rachel A. McGovern et al.
AIDS (2010)
Improved Detection of CXCR4-Using HIV by V3 Genotyping: Application of Population-Based and Deep Sequencing to Plasma RNA and Proviral DNA
Luke C. Swenson et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-Tropic HIV-1 Infection
David A. Cooper et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing
John Archer et al.
AIDS (2009)
Comparison of Human Immunodeficiency Virus Type 1 Tropism Profiles in Clinical Samples by the Trofile and MT-2 Assays
Eoin Coakley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1
Michael Saag et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantaion
Gero Huetter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The genome sequencer FLX™ system-longer reads, more applications, straight forward bioinformatics and more complete data sets
Marcus Droege et al.
JOURNAL OF BIOTECHNOLOGY (2008)
Maraviroc for previously treated patients with R5 HIV-1 infection
Roy M. Gulick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-Infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir
M Westby et al.
JOURNAL OF VIROLOGY (2006)
Structure of a V3-containing HIV-1 gp120 core
CC Huang et al.
SCIENCE (2005)
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
P Dorr et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals
ZL Brumme et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy
ZL Brumme et al.
AIDS (2004)
Share Paper
